Get expert investment analysis on the Australian stockmarket, economy and property from Rask Media’s chosen fund managers, selected analysts and writers. Stay up to date with your preferred experts by creating a free Rask account.
The key catalyst, of course, was the Fed meeting. While the Fed kept rates on hold as widely expected, the ‘dot plot’ of Fed policy expectations retained a further rate hike this year – and one less rate cut in 2024.
Up 42%, is Washington H. Soul Pattinson & Co. Ltd (ASX: SOL) a growth stock? Maybe, but probably not.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.051% to 7068.80.
NAOS’ Robert Miller dives into the case for Maxiparts Ltd (ASX:MXI), and offers an overview of Supply Network (ASX:SNL) and Bapcor (ASX:BAP).
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -1.37% to 7065.20.
No matter how experienced an investor you are, the decision of when to invest money can naturally provoke a feeling of uncertainty or apprehension.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.46% to 7163.30.
The price-to-earnings (P/E) ratio is one of the most commonly used metrics in financial analysis as it helps investors understand and compare company valuations.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
The key catalyst, of course, was the Fed meeting. While the Fed kept rates on hold as widely expected, the ‘dot plot’ of Fed policy expectations retained a further rate hike this year – and one less rate cut in 2024.
Up 42%, is Washington H. Soul Pattinson & Co. Ltd (ASX: SOL) a growth stock? Maybe, but probably not.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.051% to 7068.80.
NAOS’ Robert Miller dives into the case for Maxiparts Ltd (ASX:MXI), and offers an overview of Supply Network (ASX:SNL) and Bapcor (ASX:BAP).
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -1.37% to 7065.20.
No matter how experienced an investor you are, the decision of when to invest money can naturally provoke a feeling of uncertainty or apprehension.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.46% to 7163.30.
The price-to-earnings (P/E) ratio is one of the most commonly used metrics in financial analysis as it helps investors understand and compare company valuations.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.
